Clinical trial · Observational
The Role of ctDNA, PVT1 and ROS in Diagnosis and Treatment of Gastrointestinal and Hepatobiliary Pancreatic Cancer
NCT03076502CI-TRIAL-00026393unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the role of ct-DNA, PVT1 and reactive oxygen species (ROS) as biomarkers in the diagnosis, treatment and recurrence monitoring of gastrointestinal and hepatobiliary pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms, Gastrointestinal | Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Pathological diagnosis
- timeFrame
- intraoperative
- description
- Sensitivity and specificity
Secondary outcomes (1)
- measure
- Tumor status（worse/ maintain/ better）
- timeFrame
- 2 years
- description
- the level of ct-DNA compared with the tumor burden
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with suspected of gastrointestinal and hepatobiliary pancreatic cancer * Age from 18 - 80 years * No serious organic and mental illness; Exclusion Criteria: * Pregnancy * No pathologic result * Suffering other malignancies at the same time.
References
Publications (0)
Data not yet available
No reference posted for this study.